Silence Therapeutics plc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
SLN Nasdaq 2834 www.silence-therapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Silence Therapeutics plc

Silence Therapeutics to Participate in Three September Investor Conferences - Sep 2nd, 2026 6:00 am
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs - Aug 14th, 2026 2:55 pm
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know - Aug 13th, 2026 7:55 am
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering - Aug 11th, 2026 9:20 pm
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial - Aug 10th, 2026 11:01 pm
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares - Aug 10th, 2026 2:01 pm
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile - Aug 10th, 2026 5:30 am
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results - Aug 10th, 2026 5:15 am
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera - Aug 9th, 2026 3:00 pm
Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential - Jun 30th, 2026 7:06 am
Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains? - Jun 25th, 2026 5:48 am
How Silence Therapeutics (SLN) Is Building the Divesiran Case Around Fewer Blood Draws in Polycythemia Vera - Jun 17th, 2026 9:16 am
European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading - Jun 15th, 2026 9:09 am
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera - Jun 11th, 2026 5:30 am
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading - Jun 9th, 2026 9:11 am
This Silence Therapeutics Insider Increased Their Holding In The Last Year - May 12th, 2026 4:07 am
European Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading - Apr 22nd, 2026 9:13 am
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock? - Apr 16th, 2026 6:50 am